Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Abbott in first for Rapamune monitoring test:

This article was originally published in Clinica

Executive Summary

Abbott Laboratories has launched what is claimed to be the first commercialised automated assay for the potent immunosuppressive drug, Rapamune. The IMx sirolimus assay, which has been released in all major countries except the US, where FDA clearance is pending, was developed by Anglo-Norwegian firm Axis-Shield. Axis will manufacture the test in its Dundee, Scotland facility. Rapamune, made by Wyeth, is indicated for the prophylaxis of organ rejection in patients receiving renal transplants. Availability of the test will facilitate monitoring of sirolimus levels in transplant patients, which have to be properly maintained in each patient to optimise response, and may also encourage wider prescription of the drug in patients who may benefit from it, said Axis-Shield.

You may also be interested in...

US COVID-19 Fraud: Latest Chloride Dioxide Products Linked To Claims Are Oral Rinses

Previous businesses FDA warned about COVID-19 claims for chlorine dioxide, a bleach solution, were marketing dietary supplements unlawfully. But Pro Breath MD's oral rinses available under the Dentist Select and OraCare brands are allowed and FDA isn’t asking the firm to discontinue distribution.

CMS Removes Some Stark Law ‘Bureaucratic Barriers’ In Final Rule

The Stark Law ban on self-referrals wouldn’t apply to some physician owners of advanced imaging facilities under a CMS final rule.

Alzheimer’s Drug & Dermatitis JAK inhibitor Among New EU Filings

Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts